Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement ...

By Siddhi Mahatole Sept 17 (Reuters) - Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal ...

Novo Nordisk signs a deal worth up to $1.4bn with Orbis Medicines to develop oral drugs for cardiometabolic diseases.

Orbis Medicines announced a strategic collaboration and license agreement with Novo to discover and develop next-generation ...

Novo Nordisk (NVO) signed a strategic collaboration and license agreement with Orbis Medicines to develop oral macrocycle therapeutics for cardiometabolic diseases, Orbis said Thu ...

Novo Nordisk (OVO) teams up with Orbis Medicine to develop oral cardiometabolic treatments—in a deal worth up to $1.4B. Read ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Orbis Medicines, a leader in oral macrocycle drug ...

Orbis Medicines – a leader in oral macrocycle drug discovery – announced today the closing of a €90 million Series A funding round, bringing the total amount raised by the company to €116 million. The ...

Peptide drugs, such as the metabolic medicines Mounjaro and Zepbound from Eli Lilly, must be administered as injections. But the biotech industry has been pursuing ways to make peptides into pills, ...

For all of the benefit that biologic drugs provide as treatments for chronic conditions, these medications also require chronic dosing by injection or infusion. Biotech companies have been pursuing ...